Probucol

Probucol

Clinical data
ATC code	C10AX02 (WHO)
Identifiers
IUPAC name 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl- 4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
PubChem CID	4912
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C31H48O2S2
Molar mass	516.844 g/mol

WikiDoc Resources for Probucol
Articles
Most recent articles on Probucol Most cited articles on Probucol Review articles on Probucol Articles on Probucol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Probucol Images of Probucol Photos of Probucol Podcasts & MP3s on Probucol Videos on Probucol
Evidence Based Medicine
Cochrane Collaboration on Probucol Bandolier on Probucol TRIP on Probucol
Clinical Trials
Ongoing Trials on Probucol at Clinical Trials.gov Trial results on Probucol Clinical Trials on Probucol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Probucol NICE Guidance on Probucol NHS PRODIGY Guidance FDA on Probucol CDC on Probucol
Books
Books on Probucol
News
Probucol in the news Be alerted to news on Probucol News trends on Probucol
Commentary
Blogs on Probucol
Definitions
Definitions of Probucol
Patient Resources / Community
Patient resources on Probucol Discussion groups on Probucol Patient Handouts on Probucol Directions to Hospitals Treating Probucol Risk calculators and risk factors for Probucol
Healthcare Provider Resources
Symptoms of Probucol Causes & Risk Factors for Probucol Diagnostic studies for Probucol Treatment of Probucol
Continuing Medical Education (CME)
CME Programs on Probucol
International
Probucol en Espanol Probucol en Francais
Business
Probucol in the Marketplace Patents on Probucol
Experimental / Informatics
List of terms related to Probucol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease.

However, clinical trials were stopped after it was found that it may lower HDL in patients with a previous history of heart disease.

Probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity.

Probucol is associated with QT interval prolongation.

Mechanism

Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption. Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.

It is believed to act at ABCA1.

It also lowers levels of HDL.